ERG and prostate carcinoma: ERG overexpression resulting from the rearrangement between the TMPRSS2 promoter and the coding regions of the ERG gene has been identified as the most common alteration in prostate cancer (PrCa), accounting for more than 90% of the TMPRSS2-ETS family rearrangements [1–3].